X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7783) 7783
Book Review (1235) 1235
Publication (777) 777
Conference Proceeding (63) 63
Book Chapter (53) 53
Dissertation (18) 18
Magazine Article (1) 1
Paper (1) 1
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
sorafenib (7404) 7404
index medicus (4966) 4966
humans (4388) 4388
oncology (3299) 3299
hepatocellular carcinoma (2364) 2364
cancer (2356) 2356
male (2257) 2257
female (2113) 2113
niacinamide - analogs & derivatives (2093) 2093
middle aged (1811) 1811
aged (1602) 1602
sunitinib (1489) 1489
antineoplastic agents - therapeutic use (1388) 1388
treatment outcome (1259) 1259
adult (1154) 1154
survival (1148) 1148
liver cancer (1106) 1106
care and treatment (1068) 1068
liver neoplasms - drug therapy (1047) 1047
carcinoma, hepatocellular - drug therapy (1001) 1001
metastasis (947) 947
animals (912) 912
liver neoplasms - pathology (895) 895
therapy (891) 891
carcinoma, renal cell - drug therapy (877) 877
hepatoma (875) 875
chemotherapy (853) 853
kidney neoplasms - drug therapy (851) 851
carcinoma, hepatocellular - pathology (832) 832
phenylurea compounds (811) 811
antineoplastic agents (804) 804
prognosis (790) 790
antimitotic agents (776) 776
angiogenesis (763) 763
pharmacology & pharmacy (747) 747
apoptosis (731) 731
analysis (724) 724
renal cell carcinoma (722) 722
tumors (721) 721
efficacy (709) 709
aged, 80 and over (694) 694
cell line, tumor (693) 693
gastroenterology & hepatology (680) 680
interferon-alpha (676) 676
bevacizumab (657) 657
phenylurea compounds - therapeutic use (651) 651
protein kinase inhibitors - therapeutic use (651) 651
retrospective studies (636) 636
expression (627) 627
antineoplastic agents - pharmacology (622) 622
medicine & public health (611) 611
digestive system diseases (609) 609
antineoplastic agents - adverse effects (602) 602
drug therapy (598) 598
niacinamide - therapeutic use (596) 596
carcinoma (570) 570
disease-free survival (565) 565
trial (554) 554
kidney neoplasms - pathology (553) 553
double-blind (534) 534
mice (528) 528
research (526) 526
carcinoma, renal cell (515) 515
vascular endothelial growth factor (515) 515
endothelial growth-factor (514) 514
renal-cell carcinoma (494) 494
neoplasms (490) 490
targeted therapy (489) 489
pyridines - therapeutic use (480) 480
cancer therapies (477) 477
patients (460) 460
kinases (454) 454
phenylurea compounds - administration & dosage (453) 453
management (452) 452
phase-ii (452) 452
antineoplastic agents - administration & dosage (445) 445
antineoplastic combined chemotherapy protocols - therapeutic use (445) 445
liver (442) 442
niacinamide - administration & dosage (430) 430
medical prognosis (427) 427
transarterial chemoembolization (424) 424
benzenesulfonates - therapeutic use (423) 423
safety (421) 421
health aspects (419) 419
hepatocellular-carcinoma (418) 418
phenylurea compounds - pharmacology (416) 416
tyrosine kinase inhibitor (407) 407
cell proliferation - drug effects (406) 406
everolimus (401) 401
neoplasm staging (401) 401
niacinamide - pharmacology (390) 390
clinical trials (385) 385
urology & nephrology (385) 385
carcinoma, renal cell - pathology (380) 380
carcinoma, hepatocellular - mortality (377) 377
carcinoma, hepatocellular - therapy (377) 377
liver neoplasms - mortality (377) 377
liver neoplasms - therapy (377) 377
cell biology (375) 375
phase-ii trial (375) 375
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7270) 7270
Korean (175) 175
German (138) 138
French (118) 118
Japanese (73) 73
Spanish (39) 39
Chinese (21) 21
Russian (19) 19
Polish (12) 12
Czech (8) 8
Italian (5) 5
Portuguese (3) 3
Turkish (3) 3
Hungarian (2) 2
Slovak (2) 2
Catalan (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Therapeutic Research, ISSN 0289-8020, 2015, Volume 36, Issue 4, pp. 371 - 375
Journal Article
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 06/2019, Volume 17, Issue 6, pp. 758 - 760
Journal Article
by Qi, XS and Jia, J and Fan, DM and Han, GH
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 03/2014, Volume 32, Issue 9, pp. 968 - 968
Journal Article
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, ISSN 1759-5045, 03/2017, Volume 14, Issue 3, pp. 141 - 142
Drug development in hepatocellular carcinoma had essentially stalled since 2008 when sorafenib was established as the modest standard of care. Now, a positive... 
SORAFENIB | GASTROENTEROLOGY & HEPATOLOGY
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 1737, Volume 111, Issue 14, pp. 5319 - 5324
Journal Article
Molecules, ISSN 1420-3049, 2018, Volume 23, Issue 1, p. 24
Both EGFR and VEGFR-2 play a critical role in tumor growth, angiogenesis and metastasis, and targeting EGFR and VEGFR-2 simultaneously represents a promising... 
Thiourea | Quinazoline | Sorafenib | Molecular docking | TK inhibitor | ANTITUMOR AGENTS | quinazoline | thiourea | molecular docking | sorafenib | BIOCHEMISTRY & MOLECULAR BIOLOGY | GROWTH | BIOLOGICAL-ACTIVITIES | DERIVATIVES | CHEMISTRY, MULTIDISCIPLINARY | Quinazolines - chemical synthesis | Thiourea - therapeutic use | Antineoplastic Agents - chemical synthesis | Humans | Melanoma, Experimental - drug therapy | Antineoplastic Agents - therapeutic use | Thiourea - pharmacology | Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors | Thiourea - chemical synthesis | Drug Design | Antineoplastic Agents - pharmacology | Cell Survival - drug effects | Molecular Docking Simulation - methods | ErbB Receptors - antagonists & inhibitors | Mice, Inbred C57BL | Sorafenib - chemical synthesis | Sorafenib - analogs & derivatives | Sorafenib - pharmacology | Sorafenib - therapeutic use | Xenograft Model Antitumor Assays | Animals | Quinazolines - therapeutic use | Cell Line, Tumor | Protein Binding | Cell Proliferation - drug effects | Quinazolines - pharmacology | Biotechnology | Model testing | Epidermal growth factor receptors | Melanoma | Thioureas | Kinases | Vascular endothelial growth factor receptors | Anticancer properties | Metastases | Analogs | Angiogenesis | Inhibitors | Antitumor agents | Cell lines | Xenografts | In vivo methods and tests | Cancer | Index Medicus
Journal Article
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, 12/2018, Volume 16, Issue 12, pp. 1486 - 1489
Journal Article
Marmara Medical Journal, ISSN 1019-1941, 01/2019, pp. 33 - 37
Journal Article
08/2011
Background: The relationship of epidermal growth factor receptors (EGFR) pathway, such as PI3K, K-ras, and B-raf, with response to EGFR-targeted antibodies is... 
metastatic colorectal carcinoma | sorafenib | K-ras | cetuximab
Web Resource
ONCOLOGY RESEARCH AND TREATMENT, ISSN 2296-5270, 2018, Volume 41, Issue 3, pp. 147 - 147
Journal Article
Hepatology, ISSN 0270-9139, 07/2019, Volume 70, Issue 1, pp. 429 - 430
On July 5 , 2018, the final results of the CELESTIAL trial were published on the authoritative pages of the New England Journal of Medicine (1); in this... 
SORAFENIB | GASTROENTEROLOGY & HEPATOLOGY | Hepatocellular carcinoma | Patients
Journal Article
Journal Article
Journal Article
Acta Biomaterialia, ISSN 1742-7061, 07/2018, Volume 75, pp. 413 - 426
Sorafenib (So) is a multi-target kinase inhibitor extensively used in clinic for hepatocellular carcinoma therapy. It demonstrated strong inhibition both in... 
Hepatocellular carcinoma | Anti-angiogenesis | Reconstituted high density lipoprotein | Sorafenib | antimiRNA21 | GRAPHENE OXIDE | MATERIALS SCIENCE, BIOMATERIALS | ANGIOGENESIS | ENGINEERING, BIOMEDICAL | MICRORNA-21 | CANCER-THERAPY | CHEMOTHERAPY | DELIVERY | NANOPARTICLES | IN-VIVO | TUMOR-SUPPRESSOR | LIPOSOMES | Human Umbilical Vein Endothelial Cells | Lipoproteins, HDL - pharmacokinetics | MicroRNAs - antagonists & inhibitors | Humans | MicroRNAs - metabolism | Sorafenib - chemistry | RNA, Neoplasm - metabolism | Lipoproteins, HDL - pharmacology | Carcinoma, Hepatocellular - drug therapy | Carcinoma, Hepatocellular - genetics | Lipoproteins, HDL - chemistry | RNA, Neoplasm - antagonists & inhibitors | Female | Liver Neoplasms - pathology | Oligopeptides - chemistry | Liver Neoplasms - genetics | Oligopeptides - pharmacokinetics | Sorafenib - pharmacokinetics | Liver Neoplasms - drug therapy | Sorafenib - pharmacology | Hep G2 Cells | Animals | Carcinoma, Hepatocellular - pathology | Liver Neoplasms - metabolism | RNA, Neoplasm - genetics | Mice | Mice, Inbred BALB C | MicroRNAs - genetics | Oligopeptides - pharmacology | Carcinoma, Hepatocellular - metabolism | Effectiveness | Toxicity | Organs | Oligonucleotides | Parenchyma | Antisense oligonucleotides | Ribonucleic acid--RNA | Drug resistance | Apolipoproteins | Density | Anticancer properties | Nanoparticles | Liver cancer | Prescription drugs | Angiogenesis | Apolipoprotein A | Lipoproteins | Chemotherapy | Side effects | Receptors | Apolipoprotein A-I | Biocompatibility | Tumors
Journal Article
Journal Article
Acta Biomaterialia, ISSN 1742-7061, 05/2018, Volume 72, pp. 248 - 255
Proposed mechanism of miR-375/Sf-LCC NPs for anti-tumor effects and autophagy inhibition in HCC. Sorafenib is a first-line drug for hepatocellular carcinoma... 
microRNA | Hepatocellular carcinoma | Nanoparticle | Nanomedicine | Autophagy | Cancer | DRUG | CELLS | MATERIALS SCIENCE, BIOMATERIALS | ENGINEERING, BIOMEDICAL | TUMOR | SORAFENIB | CHLOROQUINE | MULTIKINASE INHIBITOR | CHEMOTHERAPY | DELIVERY | BREAST-CANCER | MIR-375 | Nanoparticles - chemistry | Humans | Coated Materials, Biocompatible - pharmacology | Delayed-Action Preparations - chemistry | MicroRNAs - pharmacokinetics | Sorafenib - chemistry | MicroRNAs - pharmacology | Calcium Carbonate - chemistry | Lipids - chemistry | Carcinoma, Hepatocellular - drug therapy | Lipids - pharmacology | Nanoparticles - therapeutic use | Delayed-Action Preparations - pharmacology | Delayed-Action Preparations - pharmacokinetics | Liver Neoplasms - pathology | Calcium Carbonate - pharmacokinetics | Coated Materials, Biocompatible - pharmacokinetics | Sorafenib - pharmacokinetics | Liver Neoplasms - drug therapy | Coated Materials, Biocompatible - chemistry | Sorafenib - pharmacology | Hep G2 Cells | Xenograft Model Antitumor Assays | Animals | Lipids - pharmacokinetics | Mice, Nude | Carcinoma, Hepatocellular - pathology | Liver Neoplasms - metabolism | Mice | Calcium Carbonate - pharmacology | MicroRNAs - chemistry | Carcinoma, Hepatocellular - metabolism | Antimitotic agents | Nanoparticles | Pharmacy | Analysis | Calcium carbonate | Drugstores | Hepatoma | Antineoplastic agents | Drug delivery systems | Calcium | Toxicity | Liver | Xenotransplantation | Cytotoxicity | Retention time | pH effects | Coatings | Cobalt | Anticancer properties | Liver cancer | Cellular biology | Xenografts | Biocompatibility | Nanostructured materials | Phagocytosis | Tumors | Index Medicus
Journal Article
BMC Cancer, ISSN 1471-2407, 04/2018, Volume 18, Issue 1, pp. 392 - 392
Journal Article
Cancer Letters, ISSN 0304-3835, 07/2018, Volume 425, pp. 101 - 115
Molecular targeted compounds are emerging as a strategy to improve classical chemotherapy. Herein, we describe that using low dose of the multikinase inhibitor... 
Inflammation | Secretome | MEK1/2-ERK1/2 | Sorafenib | Alkylation | RAS ACTIVATION | OXIDATIVE STRESS | MATRIX-METALLOPROTEINASE | PACLITAXEL RESISTANCE | TUMOR-CELLS | ANTITUMOR-ACTIVITY | RAF/MEK/ERK PATHWAY | INHIBITOR SORAFENIB | ONCOLOGY | NF-KAPPA-B | BLOOD-CELLS | Cell Survival - drug effects | Cyclophosphamide - administration & dosage | Sorafenib - administration & dosage | Humans | Antineoplastic Agents, Alkylating - pharmacology | Antineoplastic Agents, Alkylating - administration & dosage | Sorafenib - pharmacology | Breast Neoplasms - drug therapy | Breast Neoplasms - metabolism | Drug Synergism | Xenograft Model Antitumor Assays | Cell Movement - drug effects | Animals | MCF-7 Cells | Signal Transduction - drug effects | Neovascularization, Pathologic - drug therapy | Cyclophosphamide - pharmacology | Cell Line, Tumor | Female | Cell Proliferation - drug effects | Mice | Gene Expression Regulation, Neoplastic - drug effects | Genes | Development and progression | Breast cancer | Metastasis | Antineoplastic agents | Gene expression | Proteins | Antimitotic agents | Chemotherapy | Analysis | Cancer cells | Cancer | Reactive oxygen species | Phosphorylation | Toxicity | Xenotransplantation | Paracrine signalling | Cytotoxicity | Kinases | Cancer therapies | Metastases | Anticancer properties | Angiogenesis | Cell cycle | Xenografts | Autocrine signalling | Interleukin 8 | Phenotypes | Cell survival | Cytokines | Invasiveness | Alkylating agents | Extracellular signal-regulated kinase | Cyclophosphamide | Breast | Antitumor activity | Cyclooxygenase-2 | Tumors | Index Medicus | alkylation | MEK1 | 2-ERK1 | sorafenib | secretome | inflammation
Journal Article